These results are in line with the study by Ward et al., which demonstrated that combination treatment with an anti-CD19 antibody and rituximab resulted in decreased tumor growth in lymphoma mouse models compared to the respective mono-treatments (56). This evidence concerns the gene CD19 and neoplasm.